Healthcare Industry News: Cook
News Release - October 20, 2006
Takeda Celebrates U.S. Growth with Grand Opening of New Home OfficeMilestone Reflects Rapid Growth in Product Portfolio and Progress in Becoming a World Class Pharmaceutical Company
DEERFIELD, Ill., Oct. 20 (HSMN NewsFeed) -- Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. celebrate today the grand opening of the companies' new, 70-acre corporate home office in Deerfield, Ill. Several representatives from the companies' Japanese parent company, Takeda Pharmaceutical Company Limited, will join local dignitaries and employees on-site at One Takeda Parkway to commemorate Takeda's history and growth in the U.S.
"We are celebrating yet another milestone for Takeda. In just eight years, the company quickly grew in the United States from three employees to more than 3,000, establishing itself as the one of the fastest-growing pharmaceutical companies in the United States," said Mark Booth, president of Takeda Pharmaceuticals North America, Inc. "This remarkable growth drove the need for a new campus to help support our continued success, and we are pleased to have found a home in Deerfield."
Takeda's new property is located at the northwest corner of the I-94 and Lake-Cook Road intersection. This first phase of construction, which includes a 380,000 square-foot campus consisting of two buildings, houses Takeda's more than 800 home office employees. The campus now consists of two office buildings, including a cafeteria, general store, fitness center and a 5,300 square-foot remote delivery facility.
Takeda was awarded more than $15 million in Opportunity Returns support by the Illinois Department of Commerce and Economic Opportunity (DCEO) that enabled the company to relocate its home office operations to Deerfield, Ill. Opportunity Returns is a regional economic development strategy with the goal of successfully partnering with companies and communities, both large and small, to help all of Illinois reach its economic potential.
"The opening of the new Takeda home office in the United States is one of our greatest achievements for establishing and enhancing our U.S. business," said Kunio Takeda, chairman of the board of Takeda Pharmaceutical Company Limited. "This event represents the realization of a long-cherished dream passed down from our predecessors to the current management and throughout the 225-year history of Takeda."
Takeda Pharmaceuticals North America, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. In the United States, Takeda currently markets oral diabetes, insomnia, gastroenterology and cholesterol lowering treatments, and through the Takeda Global Research & Development Center, Inc. the company has a robust pipeline with compounds in development for diabetes, cardiovascular disease and other conditions. Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. To learn more about the company and its products, visit http://www.tpna.com .
Source: Takeda Pharmaceuticals North America
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.